EIF4A2

Across TCGA pan-cancer cohorts, EIF4A2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EIF4A2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher EIF4A2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EIF4A2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

GBM, UCEC, and LUAD are the cancer types where EIF4A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.275	0.565	.024	8	view →
UCEC	OS	Tertile	II,III,IV	0.568	1.000	.026	8	view →
LUAD	DFS	Median	All	0.746	0.511	.008	4	view →
LSCC	DFS	Median	All	0.937	0.608	.021	3	view →
HNSC	OS	Median	All	0.629	0.777	.032	3	view →
CCRCC	DFS	Median	All	0.821	0.643	.020	3	view →
PDAC	DFS	Median	All	0.809	0.640	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EIF4A2–GBM (DFS)

Open the GBM breakdown →